Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Other Events
Item 8.01
| Other Events. |
On May 9, 2017, Array issued a press release announcing the
top-line results from Part 2 of the Phase 3 clinical trial of
binimetinib and encorafenib in patients with advanced BRAF-mutant
melanoma, known as the COLUMBUS trial.
A copy of the press release is attached to this Form 8-K as
Exhibit99.1 and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits
| ExhibitNo. | Description | |
| 99.1 |
Press release announcing the top-line results from Part 2 of the ongoing Phase 3 clinical trial of binimetinib and encorafenib in patients with advanced BRAF-mutant melanoma |
About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382. Array BioPharma Inc. (NASDAQ:ARRY) Recent Trading Information
Array BioPharma Inc. (NASDAQ:ARRY) closed its last trading session up +0.06 at 7.02 with 6,158,332 shares trading hands.